Dr. Chong-Xian Pan

University of California Davis Cancer Center, USA

Email: cxpan@ucdavis.edu

Qualifications

2007  Ph.D., University of California at Davis, USA

1999  Ph.D., Loyola University Chicago, USA

1989  M.Sc., Fudan University, China

Publications (Selected)

1. Karen G. Chee, Jeff Longmate, David I. Quinn, Gurkamal Chatta, Jacek Pinski, Przemyslaw Twardowski, Chong-Xian Pan, Angelo Cambio, Christopher P. Evans, David R. Gandara, and Primo N. Lara Jr. The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial. Clinical Genitourinary Cancer. 2007; 5:433-437.
2. Luo J, Zhang H, Xiao W, Kumaresan PR, Shi C, Pan C, Aina OH and Lam KS. Rainbow beads: a color coding method to facilitate high-throughput screening and optimization of one-bead one-compound combinatorial libraries. J. Comb Chem. 2008. 10:599-604.
3. Yu Wang, Margarita Mikhailova, Swagata Bose, Chong-Xian Pan, Ralph W. deVere White and Paramita M. Ghosh. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008. 27: 7106-7117.
4. Michael S. Gordon, Michael Hussey, Raymond. Nagle, Primo N. Lara, Jr., Philip C. Mack, Janice Dutcher,Wolfram Samlowski, Joseph I. Clark, David I. Quinn, Chong-Xian Pan, David Crawford. A Phase II Study of Erlotinib (OSI-774) in Patients with Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317. J. Clinical Oncology. 2009. 2009. 27: 5788-2793.
5. Paul Henderson, Chong-xian Pan. Human microdosing for the prediction of patient response. Bioanalysis. 2010. 2:373-376.
6. Rasanamar Sandhu, Chong-xian Pan, Theodore Wun, Danielle Harvey, Hong Zhou, Richard H. White, Helen K. ChewThe Incidence of Venous Thromboembolism and its Effect on Survival Among Patients With Primary Bladder Cancer. Cancer. 2010: 116:2596-2603.
7. Sisi Wang, Hongyong Zhang, Michael Malfatti, Ralph de Vere White, Primo N. Lara, Jr., Kenneth Turteltaub, Paul Henderson, Chong-xian Pan. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chemical Research in Toxicology. 2010. 23:1653-1655.
8. Sisi Wang, Hongyong Zhang, Liang Cheng, Christopher Evans and Chong-Xian Pan. Analysis of the Cytotoxic Activity of the Carboplatin and Gemcitabine Combination. Anticancer Research. 2010. 30: 4573-4578.
9. Paul T. Henderson, Tao Li, Miaoling He, Hongyong Zhang, Michael Malfatti, David Gandara,  Peter P. Grimminger, Kathleen D. Danenberg, Laurel Beckett, Ralph W. de Vere White, Kenneth W. Turteltaub, and Chong-xian Pan. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. International Journal of Cancer. 2011; 129:1425-1434.
10. Tzu-yin Lin, Hongyong Zhang, Sisi Wang, Li Xie, Bin Li, Carlos O. Rodriguez, Jr., Ralph de Vere White, Chong-xian Pan. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Molecular Cancer. 2011. 10:9.
11. Liang Cheng, Shaobo Zhang, Riley Alexander, Yongxue Yao, Gregory T. MacLennan, Chong-xian Pan, Jiaoti Huang, Mingsheng Wang, Rodolfo Montironi, Antonio Lopez-Beltran. The landscape of EGFR pathways and personalized management of nonsmall cell lung cancer. Future Oncology. 2011. 7:519-541.
12. Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN Jr. A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. Int J. Clin Oncol. 2011. 16:494-9.
13. L. Cheng, R. Alexander, S. Zhang, C-X. Pan, G. T. MacLennan, A. Lopez-Beltran and R. Montironi. The clinical and therapeutic implications of cancer stem cell biology. Expert Review of Anticancer Therapy. 2011. 7:1133-1145.
14. Hongyong Zhang, Olulanu H. Aina, Kit S. Lam, Ralph de Vere White, Li (Sherlly) Xie,  Liang Cheng, Xiaobing Wang, Primo N. Lara, Christopher Evans, James A. Bassuk, Alessia Shahrokh, Chong-xian Pan. Development of A Bladder Cancer-Specific Ligand Using A Combinatorial Chemistry Approach. Urological Oncology. In press.
15. R.L. Vinall., A. Z. Ripoll, S. Wang, C-X. Pan and R.W. deVere White. MiR-34a Chemo-Sensitizes Bladder Cancer Cells To Cisplatin Treatment Regardless Of P53-Rb Pathway Status. International Journal of Cancer. 2012; 130:2526-2538.
16. Amy Lei, Liang Cheng and Chong-xian Pan. Current Treatment of Metastatic Bladder Cancer and Future Directions. Expert Review of Anticancer Therapy. 2011; 11:1851-1862.
17. ames S. Chang, Primo N. Lara, Jr., and Chong-xian Pan. Progress in Personalizing Chemotherapy for Bladder Cancer. Advances in Urology. 2011. In press.
18. Thomas J. Semrad, Courtney Eddings, Chong-Xian Pan, Derick H. Lau, David Gandara, Laurel Beckett, Primo N. Lara, Jr. Feasibility Study of Intra-patient Sorafenib Dose-Escalation or Re-Escalation in Patients with Previously Treated Advanced Solid Tumors. Investigational New Drugs. 2011. In press.
19. Hongyong Zhang, Juntao Luo, Yuanpei Li, Paul T Henderson, Yanchun Wang, Sebastian Wachsmann-Hogiu, Weixin Zhao, Kit S. Lam, Chong-xian Pan. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine: Nanotechnology, Biology and Medicine. In press.
20. Tzu-yin Lin, Hongyong Zhang, Juntao Luo, Yuanpei Li, Tingjuan Gao, Primo N. Lara, Jr., Ralph de Vere White, Kit S Lam, Chong-Xian Pan.  Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. International J. Nanomedicine. 7:2793-2804.
21. Derek Shek; Benjamin Kent Tomlinson; Monica Brown; Ann  Brunson; Chong-Xian Pan; Primo Lara. Epidemiological Trends in Renal Cell Carcinoma in the Cytokine and Targeted Therapy Eras: A Registry Analysis of 28,252 Patients. Clinical Genitourinary Cancer. 2012; 10:93-98.